Yüklüyor......
Early presentation of pembrolizumab-associated pneumonitis
Pembrolizumab is a selective anti-PD-L1 humanised monoclonal antibody approved by the Food and Drug Administration for treating multiple cancers, including cervical cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and squamous head and neck cancer. Pneumonitis is a r...
Kaydedildi:
| Yayımlandı: | BMJ Case Rep |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286739/ https://ncbi.nlm.nih.gov/pubmed/34266820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-242493 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|